SecBot SecBot
DEFA14A ·Filed Apr 28, 2026

TARA

Protara Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago SEC0001213900-26-048556
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the annual meeting outcome for approval of the authorized share increase and equity plan amendment, which could signal future dilution. No immediate trading action warranted; the filing is routine.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.17
T+0 close · Apr 28, 2026 · via day close
Latest settled
−22.24%
T+60 · $4.02
Vs SPY
−26.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $5.17entry
  2. T+1 · 7mo ago +3.09%α +2.07% · $5.33
  3. T+5 · 7mo ago +9.48%α +6.37% · $5.66
  4. T+20 · 6mo ago −8.12%α −14.17% · $4.75
  5. T+60 · 4mo ago −22.24%α −26.35% · $4.02

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protara Therapeutics filed definitive additional proxy materials for its 2026 Annual Meeting of Stockholders to be held on June 12, 2026. The board recommends voting FOR all director nominees, ratification of Ernst & Young as auditor, advisory approval of executive compensation, the equity incentive plan amendment, the increase in authorized shares from 100M to 200M, and officer exculpation, with a 1-year frequency for say-on-pay votes. This is a routine proxy solicitation with no contested matters or material financial disclosures.

Key Financial Metrics

Meeting
2026-06-12

Key Facts

  • Annual meeting scheduled for June 12, 2026 at 12:00 PM ET
  • Proposals include election of three Class III directors, ratification of Ernst & Young, advisory say-on-pay, frequency vote, amendment to 2024 Equity Incentive Plan, increase in authorized shares from 100M to 200M, and officer exculpation amendment
  • Board recommends FOR all proposals and 1 YEAR for say-on-pay frequency
  • No financial data or material business changes disclosed in the filing

Financial Impact

No material financial impact disclosed; routine governance proposals only.

Risk Factors

  • Potential dilution if authorized share increase and equity plan amendments are approved and utilized
  • No operational or financial updates provided in this filing

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-048556
Document: 0001213900-26-048556-index-headers.html0001213900-26-048556
Document: 0001213900-26-048556-index.html0001213900-26-048556
Document: 0001213900-26-048556.txt0001213900-26-048556

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026